Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

The initiative also would have authorized state-licensed "psychedelic therapy centers." ...

After his arrest, he told a forensic psychiatrist that this drove his offending, saying he goes “crazy” without tobacco. A ...

Discover how metabolic ketogenic therapy differs from the popular diet trend and its potential benefits for bipolar disorder.

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full ...